Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) has been given a $50.00 price target by stock analysts at Cowen and Company in a note issued to investors on Monday. The brokerage presently has a “buy” rating on the specialty pharmaceutical company’s stock. Cowen and Company’s price target suggests a potential upside of 20.48% from the stock’s current price.

SUPN has been the subject of a number of other research reports. Stifel Nicolaus lowered Supernus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $47.00 price objective for the company. in a research report on Tuesday, September 19th. They noted that the move was a valuation call. Piper Jaffray Companies restated a “hold” rating and set a $41.00 price objective on shares of Supernus Pharmaceuticals in a research report on Tuesday, September 26th. FBR & Co initiated coverage on Supernus Pharmaceuticals in a research report on Thursday, October 19th. They set a “buy” rating and a $53.00 price objective for the company. BidaskClub upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 17th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $49.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, September 27th. Four investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $48.38.

Supernus Pharmaceuticals (NASDAQ:SUPN) traded up 0.36% during midday trading on Monday, hitting $41.55. The stock had a trading volume of 324,839 shares. Supernus Pharmaceuticals has a one year low of $17.25 and a one year high of $50.04. The stock has a 50-day moving average price of $42.67 and a 200 day moving average price of $39.92. The firm has a market cap of $2.11 billion, a PE ratio of 20.96 and a beta of 1.30.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Wednesday, August 2nd. The specialty pharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.24 by $0.08. The company had revenue of $75.83 million during the quarter, compared to analyst estimates of $68.54 million. Supernus Pharmaceuticals had a return on equity of 30.73% and a net margin of 41.10%. On average, analysts predict that Supernus Pharmaceuticals will post $1.04 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Cowen and Company Analysts Give Supernus Pharmaceuticals, Inc. (SUPN) a $50.00 Price Target” was reported by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was illegally copied and reposted in violation of US and international copyright & trademark laws. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/24/cowen-and-company-analysts-give-supernus-pharmaceuticals-inc-supn-a-50-00-price-target.html.

In other Supernus Pharmaceuticals news, CFO Gregory S. Patrick sold 50,000 shares of Supernus Pharmaceuticals stock in a transaction on Friday, September 8th. The stock was sold at an average price of $47.60, for a total transaction of $2,380,000.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 3,709 shares of Supernus Pharmaceuticals stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $45.23, for a total value of $167,758.07. Following the sale, the vice president now directly owns 17,500 shares in the company, valued at approximately $791,525. The disclosure for this sale can be found here. Insiders have sold a total of 153,709 shares of company stock valued at $7,223,108 in the last 90 days. Insiders own 6.70% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the business. Pinebridge Investments L.P. raised its stake in Supernus Pharmaceuticals by 1.3% during the 2nd quarter. Pinebridge Investments L.P. now owns 6,624 shares of the specialty pharmaceutical company’s stock valued at $285,000 after acquiring an additional 86 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in Supernus Pharmaceuticals by 0.5% during the 2nd quarter. Louisiana State Employees Retirement System now owns 20,500 shares of the specialty pharmaceutical company’s stock valued at $884,000 after acquiring an additional 100 shares in the last quarter. Arizona State Retirement System raised its stake in Supernus Pharmaceuticals by 0.4% during the 2nd quarter. Arizona State Retirement System now owns 26,201 shares of the specialty pharmaceutical company’s stock valued at $1,129,000 after acquiring an additional 100 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in Supernus Pharmaceuticals by 0.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,650 shares of the specialty pharmaceutical company’s stock valued at $1,579,000 after acquiring an additional 128 shares in the last quarter. Finally, CS Mckee LP raised its stake in Supernus Pharmaceuticals by 0.5% during the 2nd quarter. CS Mckee LP now owns 42,050 shares of the specialty pharmaceutical company’s stock valued at $1,812,000 after acquiring an additional 200 shares in the last quarter. 94.71% of the stock is currently owned by hedge funds and other institutional investors.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.